Novartis AG ADR (NVS)vsSynergy CHC Corp. Common Stock (SNYR)
NVS
Novartis AG ADR
$148.38
-2.52%
HEALTHCARE · Cap: $289.19B
SNYR
Synergy CHC Corp. Common Stock
$0.23
-6.68%
HEALTHCARE · Cap: $2.93M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 204131% more annual revenue ($56.58B vs $27.70M). NVS leads profitability with a 23.9% profit margin vs -57.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
SNYR
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-65.2%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for SNYR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Smaller company, higher risk/reward
Weak financial health signals
ROE of -361.1% — below average capital efficiency
Revenue declined 32.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SNYR
The strongest argument for SNYR centers on Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : SNYR
The primary concerns for SNYR are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while SNYR is a turnaround play — different risk/reward profiles.
SNYR carries more volatility with a beta of 0.51 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 29/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Synergy CHC Corp. Common Stock
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Synergy CHC Corp. The company is headquartered in Westbrook, Maine.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?